

XVIVO Perfusion – Consensus estimates Q4 2025

Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.

Number of contributors: 6 (all of which have been updated or confirmed before the report)

KPI (MSEK, unless otherwise specified)	Q4 2025E
Net sales	214
Organic growth in local currency (%)	2.70
Gross profit	160
EBITDA	43.2
EBIT	25.5
Net profit	19.1
Earnings per share (SEK)	0.60

XVIVO Perfusion's Q4 report will be released on Tuesday 27 January at 07.30 CET.